Posted by Kerin Higa on Jun 9, 2014 in BioGPS, GeneOfTheWeek | 0 comments
circadian rhythm heart with our Dothraki #GeneOTW: Beta-Klotho
This week’s gene is Beta-Klotho (KLB).
Sounds pretty epic, right?
To be honest, I chose to write about KLB because it sounds like it belongs in Game of Thrones.
I thought I could make this into a really fun GoT-themed GotW post, in which I could pretend KLB was some sort of crazy Dothraki gene or something exciting like that. Everyone would have loved it and probably would have read the post aloud at every party for the rest of the summer (and by “everyone,” I mean me). But as I read more about it, KLB sounded far from epic. And mutations in KLB cause problems that no one wants to talk about at a party…
(But actually, it gets better, so keep reading.)
Diarrhea-Prominent Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common disorder characterized be abdominal discomfort and altered bowel function. There are different types of IBS, including constipation-predominant (IBS-C) and diarrhea-predominent (IBS-D) variations. Even if you are The Queen of Jordan, no one actually wants to hear about your IBS.
This may occur due to a disruption in FGF19 signaling, which negatively regulates BA production:
These findings are exciting, because they provide insight into the mysteries of colonic transit and IBS-D. Perhaps direct modulation of the BA pathway (shown above) could help treat IBS-D. Knowing how specific genetic targets, such as FGF19, FGFR4, and KLB, interact with environmental stresses will also elucidate the development and onset of IBS-D. But still, I don’t really want to talk about IBS..
Just your average β-Klotho:
Based on the above section, you can imagine that after some preliminary research, I was not too thrilled about my gene choice. First, I am not a huge fan of bathroom humor for science (no offense, it can be cool). Second, β-Klotho just doesn’t seem that necessary for everyday function. Bile acid production is redundantly regulated, so loss of KLB just doesn’t seem like a big deal4. For example, the group that first discovered KLB made a mouse line that does not express the gene (“Klb(-/-)”)5. For the most part, the mice were fine. They were slightly underweight, but viable and fertile (though they had elevated BA levels and might have suffered from diarrhea..). If a knockout mouse can develop normally, that’s great for the mouse, but not as exciting for a blog post.
Luckily, I continued reading and found out that excess rather than reduced FGF21-β-Klotho signaling has proven to be rather interesting and therapeutic.
FGF-KLB signaling is kinda cool
Exogenous administration of FGF21 causes anti-diabetic, lipid-lowering, weight-reducing effects in rodents, non-human primates, and humans! Now that’s exciting. These findings make the FGF21-β-Klotho signaling pathway attractive for the treatment of metabolic disorders. Activation of this pathway results in increased body temperature, enhanced fatty acid metabolism, increased insulin sensitivity, increased energy expenditure (without an increase in caloric intake), upregulated glucose transporter (GLUT1), and lowered white adipose tissue to brown adipose tissue ratio (WAT/BAT)6 . Meanwhile, thyroid hormone and adrenaline levels remain unaffected.
In obese patients, the relative expression of FGF19 and FGF21 is altered. In addition, levels of KLB expression are decreased in fat tissue but increased significantly in liver. It is unclear now how these levels are related to obesity and type-2 diabetes (increased KLB expression in the liver may be compensatory for decreased FGF19), but FGF21, β-Klotho, and now also FGF19, may provide crucial new targets for the treatment of metabolic diseases, such as diabetes and obesity78.
It gets better
So, okay, KLB antibodies could be useful for the treatment of metabolic disorders. That could be cool. But it gets even better.
FGF21 is secreted by the liver during fasting. As mentioned above (but for the endogenous version this time), FGF21 can suppress physical activity, lower insulin, inhibit growth, alter circadian behavior, and increase lifespan. Bookout et al. (2013) recently discovered that if the KLB gene in the suprachiasmatic nucleus (SCN) is deleted, these effects of FGF21 disappear. The same group (from the “Mango” lab) also found that FGF21 is responsible for the inhibition of female fertility during starvation9. Therefore, brain β-Klotho is important for the behavioral/circadian and metabolic response to starvation. And if I am ever stranded in the desert with my khalasar, I really hope my people have fully functioning FGF21-β-Klotho signaling.
In addition, here are a couple more cool things about KLB. Klb(-/-) mice exhibited resistance to gallstone formation. So maybe the β-Klotho system can be targeted for gallstone treatment10?! And even better, FGF4-β-Klotho interactions are necessary for the induction of apoptosis to inhibit hepatic tumor growth11! FGF4-β-Klotho signaling can also control the growth of non-hepatic cells, so ectopic expression of both genes may be useful for suppressing the growth of other types of tumors in vivo .
So actually, KLB is really interesting and a hot new target for metabolic disease, cancer treatments, and most recently, obesity-related heart disease12. Plus, it gave me an excuse to talk about Angie Jordan, and I still got to reference GoT 😉
- Adams, A. C., Cheng, C. C., Coskun, T., & Kharitonenkov, A. (2012). FGF21 requires βklotho to act in vivo. PloS One, 7(11), e49977. doi:10.1371/journal.pone.0049977 [↩]
- Wong, B. S., Camilleri, M., Carlson, P. J., Guicciardi, M. E., Burton, D., McKinzie, S., … Gores, G. J. (2011). A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology, 140(7), 1934–42. doi:10.1053/j.gastro.2011.02.063 [↩]
- Camilleri, M., Klee, E. W., Shin, A., Carlson, P., Li, Y., Grover, M., & Zinsmeister, A. R. (2014). Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit. American Journal of Physiology. Gastrointestinal and Liver Physiology, 306(1), G13–26. doi:10.1152/ajpgi.00294.2013 [↩]
- Wang, L., Lee, Y.-K., Bundman, D., Han, Y., Thevananther, S., Kim, C. S., … Moore, D. D. (2002). Redundant pathways for negative feedback regulation of bile acid production. Developmental Cell, 2(6), 721–31. [↩]
- Ito, S., Fujimori, T., Furuya, A., Satoh, J., & Nabeshima, Y. J Clin Invest. (2005). Impaired negative feedback suppression of bile acid synthesis in mice lacking β Klotho, 115(8). doi:10.1172/JCI23076.2202 [↩]
- Gimeno, R. E., & Moller, D. E. (2014). FGF21-based pharmacotherapy – potential utility for metabolic disorders. Trends in Endocrinology and Metabolism: TEM, 1–9. doi:10.1016/j.tem.2014.03.001 [↩]
- Zhang J., Li Y.(2014) Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov Today, 19(5):579–589. PMID: 24189035 [↩]
- Fu T., Choi S.E., Kim D.H., Seok S., Suino-Powell K.M., Xu H.E., Kemper J.K. (2013) Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. Proc Natl Acad Sci, 109(40):16137–42. PMID: 22988100 [↩]
- Owen, B. M., Bookout, A. L., Ding, X., Lin, V. Y., Atkin, S. D., Gautron, L., … Mangelsdorf, D. J. (2013). FGF21 contributes to neuroendocrine control of female reproduction. Nature Medicine, 19(9), 1153–6. doi:10.1038/nm.3250 [↩]
- Krawczyk M., Acalovschi M., Lammert F. (2013) Genetic study of FGF19 receptor variants in gallstone disease. Hepatology, 56(6):2424. PMID: 22619029 [↩]
- Luo, Y., Yang, C., Lu, W., Xie, R., Jin, C., Huang, P., … McKeehan, W. L. (2010). Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. The Journal of Biological Chemistry, 285(39), 30069–78. doi:10.1074/jbc.M110.148288 [↩]
- Patel V., Adya R., Chen J., et al. (2014) Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One. 3;9(2):e87102. doi: 10.1371/journal.pone.0087102. eCollection 2014. PubMed PMID: 24498293; PubMed Central PMCID: PMC3911936 [↩]